Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XYLO: Switching from High-Sodium Oxybate to Xywav in Narcolepsy
NCT05869773Phase 4Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jun 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 4 trial of sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate in narcolepsy, sponsored by Jazz Pharmaceuticals plc. Started Jun 2023; status: completed.
02
Drugs
sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT05869773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869773.